Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation

Radotinib (Supect™) was developed to treat chronic myeloid leukemia (CML) as a BCR-ABL1 tyrosine kinase inhibitor (TKI). Other TKIs, including imatinib and nilotinib, were also developed for treatment of CML, and recent studies were increasing about the therapeutic effects of other TKIs on solid tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Kyung Eun, Park, Sunyoung, Cheon, Soyoung, Kim, Dong Yeon, Cho, Dae Jin, Park, Jeong Min, Hur, Dae Young, Park, Hyun Jeong, Cho, Daeho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330826/
https://www.ncbi.nlm.nih.gov/pubmed/30687767
http://dx.doi.org/10.1155/2018/9580561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330826/
https://www.ncbi.nlm.nih.gov/pubmed/30687767
http://dx.doi.org/10.1155/2018/9580561

Ejemplares similares